SCHEMBL2997840

SCHEMBL2997840

O=Cc1cc(C(=O)O)cc(C(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.48
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
RXRG P48443 1/20 0.47
UNG P13051 1/20 0.47
ALDH1A1 P00352 1/20 0.44
SRD5A2 P31213 3/20 0.44
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MRGPRX4 Q96LA9 2/20 0.40
MAOB P27338 1/20 0.40
RPS6KA3 P51812 1/20 0.38
JAK3 P52333 1/20 0.38
SLC6A2 P23975 1/20 0.38
P2RY14 Q15391 1/20 0.38
TRIM24 O15164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22409981 0.84 CES2 (0.47) CES2RXRARXRBRXRGSRD5A2
SCHEMBL31443003 0.84 CES2 (0.47) CES2RXRARXRBRXRGSRD5A2
SCHEMBL545011 0.82 CES2 (0.62) CES2RXRARXRBRXRGALDH1A1
SCHEMBL503980 0.82 CES2 (0.70) CES2RXRARXRBRXRGSRD5A2
SCHEMBL10544293 0.81 SMN1; SMN2 (0.50) RXRARXRBRXRGUNGALDH1A1
SCHEMBL2554127 0.80 RXRA (0.64) RXRARXRBRXRGALDH1A1AKR1C3
SCHEMBL28119413 0.80 CES2 (0.67) CES2RXRARXRBRXRGSRD5A2
Hydrochloric Acid SCHEMBL7485970 0.80 CES2 (0.67) CES2RXRARXRBRXRGSRD5A2
SCHEMBL23531146 0.80 CES2 (0.43) CES2RXRARXRBRXRGSRD5A2
SCHEMBL2770741 0.80 NOTUM (0.62) CES2ALDH1A1MAOBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US disclosed
US-20100197924-A1 PREPARATION OF AMINOTETRALIN COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-05 US disclosed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US disclosed
EP-2057146-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-05-13 EP disclosed
WO-2008042639-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-10 WO disclosed
US-7189851-B2 Condensed heterocyclic compounds as calcitonin agonists SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-20050107419-A1 Condensed heterocyclic compounds as calcitonin agonists SMITHKLINE BEECHAM CORPORATION 2005-05-19 US disclosed
WO-2003076440-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107419-A1 Condensed heterocyclic compounds as calcitonin agonists CALCRL, CALCR, CALCB CES2 2068/4885RXRA 1356/4885RXRB 1148/4885
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS FYN, ABL2, LCK CES2 3359/4885RXRA 2735/4885RXRB 1713/4885
US-20100197924-A1 PREPARATION OF AMINOTETRALIN COMPOUNDS MAP4K5, MAP4K2, MAP4K1 CES2 2724/4885RXRA 4868/4885RXRB 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.